OINDPnews


Proveris Scientific

News

Argenta to provide respiratory modeling service to AstraZeneca

AstraZeneca has entered into a multi-year agreement with Galapagos subsidiaries BioFocus and Argenta to collaborate on discovery of compounds for the treatment of respiratory and inflammatory diseases. The deal allows AstraZeneca the use of Argenta's respiratory models, including those for asthma, COPD, and inflammation. The companies did not disclose the financial … [Read more...] about Argenta to provide respiratory modeling service to AstraZeneca

Alexza reports loss of $40.5 million for 2011, reworks agreement with Grupo Ferrer

Alexza Pharmaceuticals, whose lead product, Adasuve Staccato loxapine is under review by the FDA and the EMA, has reported a net loss of $40.5 million for the year ended December 31, 2011. The company also announced that Grupo Ferrer, its partner on Adasuve in Europe and Latin America, has purchased stock in Alexza in lieu of a potential future milestone payment. … [Read more...] about Alexza reports loss of $40.5 million for 2011, reworks agreement with Grupo Ferrer

Nycomed launches Omnaris nasal spray in the Middle East

Nycomed says that it is now marketing its Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis in the United Arab Emirates (UAE). The company, a subsidiary of Takeda, says that it will launch Omnaris in other Middle East countries by the end of 2012. According to a recent survey sponsored by Nycomed, allergic rhinitis affects over a third of UAE … [Read more...] about Nycomed launches Omnaris nasal spray in the Middle East

Aradigm gets FDA clearance for Phase 3 trial of Pulmaquin

The FDA has cleared Aradigm's Investigational New Drug Application (IND) for a Phase 3 clinical trial of Pulmaquin dual release ciprofloxacin for inhalation in non-cystic fibrosis bronchiectasis. The Phase 3 program include two one-year placebo-controlled trials with 250 patients each. The company announced plans for the trials in December, 2011. Aradigm President … [Read more...] about Aradigm gets FDA clearance for Phase 3 trial of Pulmaquin

Hovione hires Colin Minchom as VP of its particle design business unit

Hovione has appointed Colin Minchom, formerly Patheon's VP of Pharmaceutical Development Services for North America, as VP of its Particle Design Business Unit. Minchom has almost 30 years experience in drug development, especially in dosage forms and delivery, and is a member of the USP expert committee on small molecules. He is also chair of the planning committee … [Read more...] about Hovione hires Colin Minchom as VP of its particle design business unit

Teva’s ProAir HFA MDI with dose counter approved by FDA

The FDA has approved Teva's ProAir HFA albuterol metered dose inhaler with a dose counter for the treatment and prevention of bronchospasm in patients 4 years of age and older. According to the company, the new product will be available by the end of 2012. Teva Global Respiratory Research and Development Senior VP Tushar Shah explained: “The dose counter is … [Read more...] about Teva’s ProAir HFA MDI with dose counter approved by FDA

Hi-Tech Pharmacal acquires line of homeopathic nasal sprays

Specialty pharmaceutical manufacturer Hi-Tech Pharmacal will pay a total of $2.5 million plus up to to $1.75 million in royalties to Dynova Laboratories for a line of homeopathic nasal sprays including the Sinus Buster and Allergy Buster brands, which Hi-Tech will sell through its Health Care Products OTC division. The Sinus Buster formulation includes capsaicin, and … [Read more...] about Hi-Tech Pharmacal acquires line of homeopathic nasal sprays